Ping An-Shionogi Initiated a New Collaboration with Ping An-Health for Real World Data (RWD) Collection and Analysis Research

OSAKA, Japan, SHANGHAI, China, June 30, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D. hereafter "Shionogi") today announced that A joint venture between Shinogi and Ping An Life Insurance Company of China, Ltd. ※1 (Headquarters: Guangdong Province, China), Ping An-Shionogi Co., Ltd. (Head Office: Shanghai, China; Chairman and CEO: Tatsumori Yoshida, hereafter "Ping An-Shionogi") and Ping An Healthcare and Technology Co., Ltd. (Head Office: Shanghai, China; Chairman and CEO: Fang Weihao, hereafter "Ping An-Health") have entered into a new business collaboration for Real World Data (RWD) collection and analysis research for patients with metabolic diseases.


In this research, Ping An-Shionogi will utilize the online healthcare platform "Ping An Good Doctor" owned by Ping An-Health and the products sold by Ping An-Shionogi. When the drug is prescribed to a patient, Ping An-Shionogi can obtain the informed consent from the patients to participate in this research and provide a wearable device and smartphone app. The wearable device and the app can provide RWD such as the patient's medication log, sleep/activity, mental state, cognitive function, and so on. Since the RWD is visualized on the app in a user-friendly style for the patient to easily understand, participants can check it by themelves. Ping An-Health will develop the original app for this research, operate the app to collect data from the patients and securely manage the healthcare data.


Through this research, Ping An-Shionogi can contribute to improving the medication adherence of patients, early detection and treatment of comorbidities, and provision of optimal healthcare services. Ping An-Health is also expected to contribute to improving the QOL of users of the company's online healthcare platform. In addition, this research will help to accelerate data-driven drug discovery, which is an important part of the research and development concept of Ping An-Shionogi. By building a digital platform that enables the collection and analysis of high-quality RWD, starting with this study in metabolic disease and the moving into CNS conditions such as dementia and depression, which is one of Shionogi’s priority areas, and continuing clinical research activity leveraging the AI technology of the Ping An Group※2, Ping An-Shionogi will work to create new drugs and services that make full use of healthcare data.


Shionogi has stated in the medium-term Business plan "Shionogi Transformation Strategy 2030 (STS2030)" that Shionogi seeks to address the issues facing patients and society by transforming ourselves from a pharmaceutical company that provides only ethical drugs to “a HaaS※3 company” that provides comprehensive healthcare services and continuously offers new value to society. Under a long-term and strong strategic partnership with the Ping An Group, Shionogi will continue to work on the realization of HaaS by synergistic cooperation combining our different strengths, science and digital techonology.


※1 Ping An Life Insurance Company of China, Ltd.; A subsidiary of Ping An Insurance (Group) Company of China Ltd. (Headquarters: Guangdong Province, China)

※2 Ping An Group; Subsidiaries and affiliates of Ping An Insurance (Group) Company of China Ltd.

※3 HaaS; Healthcare as a Service: Provide a range of healthcare services in line with customer needs, rather than only supplying pharmaceuticals.



About Outline of RWD research

This study will enroll 1,000 patients with metabolic diseases. The patients will be provided with a wearable device and a compatible app to monitor various parameters in daily life. By analyzing the data obtained, including follow up the patients, key correlations can be identified to create concept for new drugs and healthcare services, with the monitoring results such as linkages between adherence and QOL changes. The collected data will be anonymized, processed and strictly managed, and will not be taken out of China.